Redmile Group LLC increased its position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) by 137.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 332,310 shares of the biotechnology company’s stock after buying an additional 192,067 shares during the quarter. Redmile Group LLC owned about 0.40% of Aurinia Pharmaceuticals worth $2,037,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new stake in shares of Aurinia Pharmaceuticals during the first quarter valued at about $595,000. TD Asset Management Inc. acquired a new position in Aurinia Pharmaceuticals in the first quarter worth about $241,000. Credit Agricole S A acquired a new position in Aurinia Pharmaceuticals in the first quarter valued at approximately $1,393,000. FMR LLC acquired a new position in Aurinia Pharmaceuticals in the first quarter valued at approximately $42,928,000. Finally, UBS Group AG boosted its stake in Aurinia Pharmaceuticals by 13.6% in the first quarter. UBS Group AG now owns 112,314 shares of the biotechnology company’s stock valued at $824,000 after acquiring an additional 13,405 shares during the period. 27.76% of the stock is currently owned by institutional investors.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) traded down 2.69% during trading on Wednesday, hitting $6.52. 803,306 shares of the stock traded hands. The company’s market capitalization is $544.32 million. The company’s 50 day moving average is $6.40 and its 200 day moving average is $6.53. Aurinia Pharmaceuticals Inc has a one year low of $2.02 and a one year high of $10.54.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.10. The business had revenue of $0.33 million for the quarter, compared to analysts’ expectations of $0.06 million. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. On average, equities analysts forecast that Aurinia Pharmaceuticals Inc will post ($1.01) EPS for the current fiscal year.
AUPH has been the topic of a number of recent analyst reports. Zacks Investment Research raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. Vetr raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $7.35 target price on the stock in a report on Tuesday, September 19th. Seaport Global Securities reissued a “buy” rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Friday, October 6th. Cantor Fitzgerald set a $14.00 price target on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 11th. Finally, BidaskClub lowered shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. Aurinia Pharmaceuticals has an average rating of “Buy” and an average target price of $9.82.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with our FREE daily email newsletter.